Detailed comparison on parameters like NAV | Returns | Risk | Rating | Analysis
Risk | Very High | Very High |
Rating | 3.0 | 5.0 |
Min SIP Amount | ₹100 | ₹100 |
Expense Ratio | 1.02 | 1.36 |
NAV | ₹20.10 | ₹200.79 |
Fund Started | 10 Mar 2022 | 07 May 2007 |
Fund Size | ₹477.20 Cr | ₹84854.73 Cr |
Exit Load | Exit load of 0.25% if redeemed within 7 days. | Exit load of 1% if redeemed within 1 year. |
Risk
Rating
Min SIP Amount
Expense Ratio
NAV
Fund Started
Fund Size
Exit Load
1 Year | 8.82% | 7.61% |
3 Year | 24.21% | 25.90% |
5 Year | - | 29.74% |
1 Year
3 Year
5 Year
Equity | 99.82% | 93.60% |
Cash | -0.37% | 6.40% |
Equity
Cash
Top 10 Holdings |
|
|
Top 10 Holdings
Name | Assets |
|---|---|
BSE Ltd. | 4.31% |
Hero Motocorp Ltd. | 3.62% |
Dixon Technologies (India) Ltd. | 3.46% |
Suzlon Energy Ltd. | 3.44% |
PB Fintech Ltd. | 2.97% |
HDFC Asset Management Company Ltd. | 2.91% |
Coforge Ltd. | 2.75% |
Cummins India Ltd. | 2.75% |
Persistent Systems Ltd. | 2.68% |
Fortis Healthcare Ltd. | 2.60% |
Name | Assets |
|---|---|
Max Financial Services Ltd. | 4.76% |
Balkrishna Industries Ltd. | 3.54% |
Indian Bank | 3.26% |
Fortis Healthcare Ltd. | 3.18% |
AU Small Finance Bank Ltd. | 3.16% |
Coforge Ltd. | 2.93% |
The Federal Bank Ltd. | 2.91% |
Hindustan Petroleum Corporation Ltd. | 2.90% |
Glenmark Pharmaceuticals Ltd. | 2.87% |
Ipca Laboratories Ltd. | 2.80% |
Name | Karthik Kumar | Chirag Setalvad |
Start Date | 21 Aug 2025 | 28 Jun 2014 |
Name
Start Date
Description | The scheme seeks to provide returns before expenses that closely corresponds to the total returns of the NIFTY MIDCAP 50 subject to tracking errors. | The scheme seeks to provide long-term capital appreciation/income by investing predominantly in Mid-Cap companies. |
Launch Date | 10 Mar 2022 | 07 May 2007 |
Description
Launch Date